Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2007 Sep;12(17-18):777-85. Epub 2007 Aug 22.

The significance of mitochondrial toxicity testing in drug development.

Author information

1
Drug Safety Research and Development, Pfizer Inc., 10646 Science Center Drive, San Diego, CA 92121, United States. James.Dykens@Pfizer.com

Abstract

Mitochondrial dysfunction is increasingly implicated in the etiology of drug-induced toxicities. Members of diverse drug classes undermine mitochondrial function, and among the most potent are drugs that have been withdrawn from the market, or have received Black Box warnings from the FDA. To avoid mitochondrial liabilities, routine screens need to be positioned within the drug-development process. Assays for mitochondrial function, cell models that better report mitochondrial impairment, and new animal models that more faithfully reflect clinical manifestations of mitochondrial dysfunction are discussed in the context of how such data can reduce late stage attrition of drug candidates and can yield safer drugs in the future.

PMID:
17826691
DOI:
10.1016/j.drudis.2007.07.013
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center